typical clinical and instrumental findings. He learned speaking at 18 months, walking at 24 months, became continent at age 3 years, and climbed stairs and became able to get up from the floor at age 4 years. Blood chemical investigations showed elevated creatinekinase (3523 U/L, n>170 U/L). Needle electromyography was myogenic and muscle biopsy showed dystrophic features and absence of dystrophin. At age 8 years tip-toe walking developed. Since age 11 years he was permanently using a wheel-chair. Since age 16 years he was no longer able to eat independently. At, age 19 years he required a long-term oxygen therapy via an Oracle mouth mask, followed by a non-invasive positive pressure ventilation by means of a VS Ultra device (ST-mode, IPAP 18 mm Hg, EPAP 12 mm Hg, respiratory frequency 12, Tmin 1.1 seconds, Tmax 1.4 seconds, with 3 L of oxygen). Initially, he required the respirator only during the night, but later also, during the day, except when mobilized to an upright position. At age 23 years he presented with severe scoliosis and thoracic asymmetry, macroglossia, which has been only rarely described as a phenotypic feature of DMD, 4)5) and severe quadriparesis with residual distal motor functions, and club feet. The family history was negative for DMD, as well as WPW-syndrome. Cardiac involvement initially manifested as palpitations at age 19 years. Electrocardiography (ECG) at that time was normal and did not show a delta-wave. At age 23 years palpitations recurred after awaking due to a narrow complex tachycardia, which could be suc-cessfully terminated with adenosine intravenously. Blood pressure was 110/55 mm Hg. Echocardiography was normal. After resolution of the acute rhythm abnormality, ECG showed a delta-wave over all precordial recordings (Fig. 1) , leading to the diagnosis of WPW-syndrome. Ajmaline was started and catheter ablation was scheduled. Ablation of three accessory pathways (right anterior-septal with anterograde and retrograde conduction, right posterior-septal with exclusively retrograde conduction, and right posterior-lateral with exclusively retrograde conduction) (Figs. 2 and 3 ) was successfully carried out one week after starting ajmaline without complications (Fig.  4) . One day after ablation, however, a relapse of the supraventricular tachycardia occurred, which could be again relieved with ajmaline intravenously. Six days after ablation, a re-entry tachycardia recurred, which responded favorably to adenosine intravenously, but could be finally stopped only with ajmaline intravenously. On ECG, 12 days after ablation, delta-waves had disappeared, but small Qwaves over V 2-6 were recorded (Fig. 1) . To prevent tachycardia, verapamil (240 mg/d) was additionally given with success. Unfortunately, the delta-wave and re-entry tachycardias recurred four months after the ablation. After switching to propafenone, neither the delta-wave nor re-entry tachycardia recurred. 2) WPW-syndrome is a cardiac conduction abnormality, which is due to accessory conductive pathways between the atrium and the ventricle bypassing the atrioventricular (AV)-node. 7) ECG typically shows PR-shortening, a delta wave, and QRS-widening, and patients with WPW-syndrome develop supraventricular re-entry tachycardias or atrial fibrillation. WPW-syndrome may be associated with sudden cardiac death, of which, the risk is estimated to be 0.02%/patient/y. 8) The risk of sudden cardiac death is further increased in patients who additionally suffer from atrial fibrillation, 8) or rapidly anterogradely conducting pathways with short effective refractory period. WPW-syndrome may respond to drug therapy with adenosine 9) or ajmaline. The best and most effective and safe treatment of symptomatic WPW-syndrome, however, is ablation of the accessory pathways by radio-frequency ablation. 10) After ablation, high activation recovery interval-dispersion may be observed in the persisting pre-excited rhythm, but may gradually return to normal within weeks. 11) Also, in the presented patient ablation resulted in transient resolution of palpitations and disappearance of delta-waves. Why the described DMD-patient presented with three accessory pathways remains speculative. WPW-syndrome is widely believed to result from incomplete regression of fetal accessory atrio-ventricular pathways, a procedure which may occur in neuromuscular disorders or independently from the muscle disease. Arguments for sporadic accessory pathway formation in the presented patient are that he never complained about palpitations before age 19 years and that an ECG at age 19 years did not show a delta-wave. Possibly, the atrio-ventricular connections developed due to abnormal enlargement of cardiomyocytes, since swelling of cardiomyocytes brings atrial and ventricular cardiomyocytes together, as has been described in patients with PRKAG2 syndrome.
12) Absence of a deltawave on the previous ECG at age 19 years could be explained with intermittent occurrence of pre-excitation. Arguments for WPW-syndrome as a cardiac manifestation of DMD are that cardiac conduction abnormalities are a frequent finding in these patients, and that with improved survival, also previously non-reported cardiac conduction abnormalities may be seen. WPW-syndrome could also be unrelated to DMD, but clinical manifestation not earlier than at age 19 years argue against such an assumption. Why reentry tachycardias recurred after ablation is most likely due to an incomplete ablation of the right anterior-septal pathway located in the proximity of the AV-node and the HIS-bundle. This case shows that WPW-syndrome may occur in DMD-patients carrying a dystrophin mutation. The causal relation between WPWsyndrome and mutation, however, remains speculative. Repeated radio-frequency catheter ablation of accessory pathways may be necessary to completely block the re-entry mechanism in these patients.
